Introduction {#Sec1}
============

Dysregulated apoptosis is a hallmark of human cancers. Two major pathways initiate apoptosis: the extrinsic \[or death receptor (DR)\] pathway is activated in response to ligand binding of DRs superfamily members, resulting in activation of caspase-8 followed by caspase-3; the intrinsic (or mitochondrial) pathway is triggered by mitochondrial release of cytochrome c, leading to formation of Apaf-1 and cytochrome c complex with the assistance of ATP, subsequently activating caspase-9 followed by caspase-3 (reviewed in \[[@CR1]\]). Caspases are cysteine aspartyl proteases and 14 family members have been identified \[[@CR2]\]. Based on their function, location and structural characteristics, caspases are generally classified as apoptotic caspases or pro-inflammatory caspases. Typical apoptotic caspases can be subdivided into two groups: the initiator caspases (i.e. caspase-2, -8, -9 and -10); and the effector caspases (i.e. caspase-3, -6 and -7). All caspases exist as inactive zymogens (procaspases) and their activation requires proteolytic activity during apoptosis. An effector caspase is activated by an initiator caspase through cleavage at the internal Asp residue, leading to disassembly of the large and small subunit; the inhibitor caspase, however, is activated by dimerization via the signal obtained from death receptors (reviewed in \[[@CR3]\]).

Aberrant caspase expression and/or activation have been implicated in various types of cancer. High caspase-3 expression has been demonstrated in acute myelogenous leukaemia (AML) compared to the normal counterparts \[[@CR4]\]. In comparison, reduced caspase-3 expression has been observed in moderately and poorly differentiated prostate cancer specimens compared with well-differentiated prostate tumours and normal tissues \[[@CR5]\]. Loss of caspase-8 mRNA/protein expression has been demonstrated in high grade small cell lung cancers, neuroendocrine lung cancers and paediatric neuroblastoma. Previous studies have suggested that caspase-8 might act as a tumour suppressor in certain types of lung cancer and neuroblastoma \[[@CR6], [@CR7]\]. Studies have also shown that *CASP8* gene polymorphism may contribute to the increased risk of oesophageal squamous cell carcinoma \[[@CR8], [@CR9]\]. In breast cancer, in vitro studies have shown that dysregulated caspase activity is involved in chemotherapeutic resistance. One study demonstrated that restoration of caspase-3 expression, in caspase-3 deficient MCF-7 breast cancer cells, can sensitise to doxorubicin- and etoposide-induced apoptosis, suggesting caspase-3 deficiency may be a possible mechanism for chemoresistance \[[@CR10], [@CR11]\]. Furthermore, restoration of expression in MCF-7 cells restored cytochrome c- and caspase-8 -mediated activation of pro-caspase-9 \[[@CR12]\].

The calpain family, a group of proteolytic intracellular cysteine proteases (EC 3.4.22.17 Clan CA, family C02), are calcium-activated and expressed in a wide range of cells and tissues \[[@CR13]\]. Calpastatin is the only known endogenous inhibitor of calpain (reviewed in \[[@CR14]\]). The calpain system is involved in the apoptotic machinery through interaction with caspase family members; and a number of caspase family members can be proteolytically processed by calpains. Inhibition of calpain in various tumour cell lines results in p53-dependent apoptosis, cell cycle arrest, and caspase activation (i.e. caspases-2, -3, -6, -8, and -9) \[[@CR15]\]. Caspase-7 and -10 can be activated by calpain cleavage \[[@CR16]\], calpain-mediated cleavage of caspase-12 is required for endoplasmic reticulum (ER) stress-induced apoptosis \[[@CR17]\] and degradation of caspase-9 by calpain results in an inactivated form of the enzyme, unable to activate caspase-3 \[[@CR18]\].

Previous studies have demonstrated that high caspase-3 expression is significantly associated with improved prognosis in patients with non-small cell lung cancer and hepatocellular carcinomas \[[@CR19], [@CR20]\]. The expression of caspase-3 and -6 in breast cancer was not associated with clinical outcome in a small study (n = 210) \[[@CR21]\]. Calpain-1, -2 and calpastatin are extensively expressed in breast tumours, ovarian tumours, gastro-oesophageal tumours, pancreas, bile duct and ampulla tumours, and are associated with clinical outcome or treatment response \[[@CR22]--[@CR27]\]. The aim of the current study was to assess caspase-3 and -8 protein expression, their prognostic potential in early invasive breast cancer; as well as the importance of combinatorial caspase/calpain protein expression.

Materials and methods {#Sec2}
=====================

Clinical samples {#Sec3}
----------------

This immunohistochemical based study was performed using a cohort of 1902 early stage breast cancer patients treated at Nottingham University Hospitals between 1986 and 1998 with long term follow-up. Information on clinical history and outcome was maintained on a prospective basis, and patients' clinical history and tumour characteristics were assessed in a standardised manner, including age at diagnosis, tumour size, histologic stage and grade, Nottingham prognostic index (NPI), lymphovascular invasion (LVI), oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status. The median age of the patients was 55 years (ranging from 18 to 72) and the median follow-up time was 177 months (ranging from 1 to 308 months). 63.2% (1203 of 1902) of patients had stage I disease. Patients were managed under a uniform protocol, where all underwent mastectomy (n = 1067, 56.1%) or wide local excision (n = 819, 43.1%) and approximately half of the patients received radiotherapy (n = 1025, 53.9%). Systemic adjuvant treatment was given dependent upon NPI values, ER and menopausal status. Patients with an NPI value \<3.4 did not receive adjuvant chemotherapy, whereas patients with an NPI value of 3.4 or above were chosen for CMF chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil, n = 320, 16.8%) if they were ER negative or premenopausal; patients with ER positive disease were candidates for hormone therapy (n = 674, 35.4%).

Breast cancer-specific survival was defined as the time interval (in months) from the start of primary surgery to death resultant from breast cancer. ER, PR and HER2 status were available for this cohort and have been described previously \[[@CR28]\]. HER2 expression was determined by immunohistochemistry with fluorescence in situ hybridisation (FISH) used as the arbiter in cases with an immunohistochemistry score of 2. Basal like phenotype was defined as the detection of cytokeratin (CK)-5/6 and/or CK-14 expression in 10% or more of invasive breast tumour cells, irrespective of ER, PR or HER2 status \[[@CR29]\]. This study is reported in accordance with REMARK criteria \[[@CR30]\]. Nottingham Research Ethics Committee 2 approved the project under "Development of a molecular genetic classification of breast cancer R&D (No. 03HI01 REC Ref.C202313)". The clinicopathologic variables of the cohort are shown in Table [1](#Tab1){ref-type="table"}.

Table 1Clinicopathologic variables of patient cohortVariablesNo. (%)VariablesNo. (%)Age (mean ± SD, years)54.25 (±9.77)ER status ≤40165 (8.7%) Positive1370 (72.0%) \>401736 (91.3%) Negative476 (25.0%) ND1 (0.1%) ND57 (3.0%)Tumour size (mm)2.06 ± 1.14PR status ≤201185 (62.3%) Positive1035 (54.4%) \>20708 (37.2%) Negative739 (38.9%) ND9 (0.5%) ND128 (6.7%)Tumour stageHER2 status I1203 (63.2%) Positive243 (12.8%) II531 (27.9%) Negative1602 (84.2%) III160 (8.4%) ND57 (3.0%) ND8 (0.4%)Basal statusTumour grade Positive368 (19.3%) I346 (18.2%) Negative1390 (73.1%) II632 (33.2%) ND144 (7.6%) III915 (48.1%)Triple negative status ND9 (0.5%) Positive315 (16.6%)NPI4.16 ± 1.18 Negative1516 (79.7%) ≤3.4619 (32.5%) ND71 (3.7%) 3.41--5.4948 (49.8%)Breast cancer-specific survival \>5.4324 (17.0%) Alive1064 (55.9%) ND11 (0.6%) Dead505 (26.6%)Lymphovascular invasion ND333 (17.5%) Positive492 (25.9%)Recurrence Negative1070 (56.3%) Present752 (39.5%) ND340 (17.9%) Not present1103 (58.0%)Operation type ND47 (2.5%) Mastectomy1067 (56.1%)Distant metastasis WLE lumpectomy819 (43.1%) Present579 (30.4%) ND16 (0.8%) Not present1310 (68.9%)Continuous data are shown as mean ± standard deviation (SD). *NPI* Nottingham prognostic value, *WLE* wide local excision, *ER* oestrogen receptor, *PR* progesterone receptor, *HER2* human epidermal growth factor receptor 2, *ND* not determined

TMA construction and Immunohistochemistry {#Sec4}
-----------------------------------------

Caspase-3 and -8 protein expression was investigated using tissue microarrays (TMAs) by immunohistochemistry. All calpain and calpastatin protein expression was assessed previously \[[@CR23], [@CR31]\]. A single 0.6 mm tissue core was used for each patient with the core being taken from a representative tumour area as assessed by a specialist breast cancer histopathologist, as described previously \[[@CR32]\]. Freshly cut 4 μm sections of the TMAs were used for immunohistochemistry. Primary antibody specificity was confirmed using Western blotting, on a range of breast cancer cell lines, prior to immunohistochemistry. Validation of anti-caspase-3 and -8 antibody specificity was conducted by Western blotting and data is shown in Fig. [1](#Fig1){ref-type="fig"}. Equal protein loading was used however without a loading control no firm conclusions can be drawn regarding the relative expression of the proteins across the different cell lines. Validation of anti-calpain-1, -2, -9 and calpastatin antibody specificities were established in previously published studies \[[@CR22], [@CR23], [@CR31]\]. It should be noted that the anti-caspase-3 and -8 antibodies used in the current study can detect both full-length and cleaved forms of the respective proteins. Briefly, following dewaxing in xylene and rehydration in ethanol, antigen retrieval was performed in 0.01 mol/L sodium citrate buffer (pH 6.0) in a microwave, 750 W for 10 min followed by 450 W for 10 min. Caspase-3 and -8 staining were achieved using a Vectastain Universal Elite ABC Kit (Vector Laboratories, USA) and a Novolink Polymer Detection System (Leica, Denmark) following the manufacturers' protocols, respectively. Caspase-3 (1:100, Cell Signalling Technology, USA, 9662) was applied to the tissue for 1 h at room temperature, and caspase-8 (1:25, Thermo Scientific, USA, PA1-29159) was applied to the tissue for overnight at 4 °C. Immunohistochemical reactions were visualised with 3,3′-diaminobenzidine and counterstained with haematoxylin, dehydrated and fixed in xylene followed by mounting with DPX. Positive controls constituted early stage breast tumour composite sections of varying grade and negative control omitted primary antibody.

Fig. 1Antibody validation for anti-caspase-3 (*panel A*) and anti-caspase-8 (*panel B*). A single specific band, of 35 kDa, was obtained for caspase-3, and a single specific band, of 62 kDa, obtained for caspase-8. Expression, as shown, was assessed across a range of breast cancer cell lines, representing different phenotypes (MDA-MB-231, MDA-MB-435, T-47D, MCF-7 and SKBR3), human umbilical vein endothelial cells (HUVEC), fibroblasts (MRC-5), cervical cancer (HeLa) and/or colorectal cancer cells (SW480's). Expression of caspase-3 was absent, as expected, from MCF-7's

Staining was assessed at 200× magnification following high-resolution scanning (Nanozoomer Digital Pathology Scanner, Hamamatsu Photonics). Protein expression was assessed using a semi-quantitative immunohistochemistry H-score as previously described \[[@CR33]\]. The staining intensity was assessed as: none (0), weak (1), medium (2) and strong (3), and H-scores were calculated by multiplying the percentage of positive areas by the staining intensity, giving rise to a score ranging between 0 and 300. 30% of scores were examined by a second independent assessor, blind to clinicopathological and survival endpoints. Good concordance was demonstrated between both scorers (single measure intraclass correlation coefficients were 0.898 for caspase-3 and 0.732 for caspase-8). The cut point used to dichotomise immunohistochemical scores was determined in a non-biased fashion using X-tile software \[[@CR34]\].

Statistical analysis {#Sec5}
--------------------

The relationship between categorised protein expression and clinicopathologic factors were examined using Pearson's Chi square test of association (χ^2^) or Fisher's exact test if a cell count was \<5 in a 2 × 2 table. Spearman's rank test was performed to assess for correlations between the different protein expression levels. Survival curves were plotted using the Kaplan--Meier method and significance determined using the Log-rank test. Multivariate survival analysis used the Cox proportional hazards regression model. All differences were considered statistically significant at the level of *P* \< 0.05. Statistical analysis was performed using SPSS 22.0 software.

Results {#Sec6}
=======

Immunohistochemical staining {#Sec7}
----------------------------

Representative staining patterns are shown in Fig. [2](#Fig2){ref-type="fig"}. Caspase-3 and -8 expression was mainly granular/diffuse cytoplasmic staining with some heterogeneity between adjacent tumour cells, varying from weak to intense staining. Nuclear staining was observed in a small number of cases and some inflammatory cells were observed to express caspase-3 and -8. A few TMA cores were not assessed due to insufficient tumour or the core being missing, a total number of 1421 cases for caspase-3, and 1402 cases for caspase-8 were assessed. Caspase-3 had a median H-score of 80 ± 74 and ranged from 0 to 260; caspase-8 had a median H-score of 185 ± 43 and ranged from 0 to 275. The X-tile cut point for caspase-3 was 128, with 556 (39.8%) cases having high expression and 855 (60.2%) cases having low expression. The X-tile cut point for caspase-8 was 183, with 736 (52.5%) cases having high expression and 666 (47.5%) cases having low expression.

Fig. 2Representative photomicrographs at 10× magnification with 20× magnification *inset* panel and *scale bar* representing 100 μm. **a** Caspase-3 high expression; **b** caspase-3 low expression; **c** caspase-8 high expression; **d** caspase-8 low expression

Spearman's rank correlation was used to assess the correlation between caspase-3/-8, calpains, and calpastatin protein expression (Table [2](#Tab2){ref-type="table"}). As immunohistochemical expression data for calpain-1, -2, -9 and calpastatin, were available, and as there are links in the literature between both systems it was decided to explore for potential correlations between calpain system protein expression and caspase-3/-8 protein expression. It would be interesting to further investigate the correlations between caspase-3/-8 and other calpain family members once such data becomes available. Correlations were found between the expression of caspase-3 and calpain-1 (r = 0.062, *P* = 0.047) and between caspase-8 and calpastatin (r = 0.086, *P* = 0.008); although statistically significant, these correlations are of marginal biological relevance, as reflected by the low r values. In breast cancer subgroup specific settings, significant correlations were found between caspase-3 and calpain-2 expression in the basal-like subgroup (r = 0.143, *P* = 0.045); caspase-3 and calpain-2 expression in the triple-negative subgroup (r = 0.194, *P* = 0.01); caspase-8 and calpain-9 (r = 0.25, *P* = 0.019), caspase-8 and calpastatin (r = 0.22, *P* = 0.009) in the HER2+ subgroup (Table [2](#Tab2){ref-type="table"}) but, as before, are of marginal biological relevance due to the low r values.

Table 2Correlation between protein expressions in total and different subgroupsTotalHER2+Basal-likeTriple-negativeR-valueSig.R-valueSig.R-valueSig.R-valueSig.Caspase-3 Calpain-10.062**0.047**0.1260.1220.0470.5060.0760.308 Calpain-20.0620.051−0.0570.490.143**0.045**0.194**0.01** Calpain-90.0310.4430.0880.408−0.0670.467−0.0560.557 Calpastatin−0.0530.099−0.0280.7450.0580.4180.0090.908Caspase-8 Calpain-1−0.0530.092−0.0670.4020.050.485−0.0030.966 Calpain-20.0170.6060.0620.4610.0880.2280.0130.868 Calpain-90.0470.2510.25**0.019**−0.0050.957−0.0890.358 Calpastatin0.086**0.008**0.22**0.009**0.0470.515−0.0090.904Significant *P*-values are indicated by bold font

Relationship with clinicopathologic criteria {#Sec8}
--------------------------------------------

The expression of both caspase-3 and -8 was assessed for associations with clinicopathologic variables. High caspase-3 expression was significantly associated with HER2 positivity (χ^2^=6.624; df=1; *P* = 0.01). No significant association was found between caspase-8 expression and clinicopathologic variables (Table [3](#Tab3){ref-type="table"}). High caspase-3 expression was significantly associated with the occurrence of death due to breast cancer (χ^2^=6.711; df=1; *P* = 0.01), recurrence (χ^2^=8.111; df=1; *P* = 0.004) and distant metastasis (χ2 = 5.724; df=1; *P* = 0.017) (Table [3](#Tab3){ref-type="table"}).

Table 3Correlations between caspase-3/-8 protein expressions and clinicopathologic variablesVariablesCaspase-3 (N = 1421)Caspase-8 (N = 1402)LowHigh*P*-valueLowHigh*P*-valueAge (years) ≤4091 (6.4%)45 (3.2%)0.0966 (4.7%)65 (4.6%)0.494 \>40763 (53.7%)521 (36.7%)600 (42.8%)670 (47.8%)Tumour size (mm) ≤20512 (36.2%)341 (24.1%)0.943410 (29.4%)432 (30.9%)0.241 \>20339 (23.9%)224 (15.8%)252 (18.1%)302 (21.6%)Tumour stage I517 (36.5%)353 (24.9%)0.227419 (30.0%)453 (32.4%)0.578 II267 (18.9%)156 (11.0%)191 (13.7%)212 (15.2%) III68 (4.8%)55 (3.9%)52 (3.7%)69 (4.9%)Tumour grade I148 (10.5%)97 (6.9%)0.979122 (8.7%)114 (8.2%)0.219 II274 (19.4%)180 (12.7%)219 (15.7%)234 (16.8%) III429 (30.3%)288 (20.3%)321 (23.0%)386 (27.7%)NPI ≤3.4251 (17.7%)175 (12.4%)0.416203 (14.6%)215 (15.4%)0.516 3.41--5.4452 (31.9%)280 (19.8%)348 (24.9%)378 (27.1%) \>5.4148 (10.5%)109 (7.7%)111 (8.0%)140 (10.0%)LVI Positive238 (20.1%)162 (13.7%)0.456117 (15.3%)207 (17.9%)0.747 Negative484 (40.9%)300 (25.3%)349 (30.1%)425 (36.7%)Operation type Mastectomy493 (35.0%)325 (23.1%)0.99378 (27.2%)429 (30.9%)0.511 WLE356 (25.3%)235 (16.7%)283 (20.4%)299 (21.5%)ER status Positive614 (44.5%)394 (28.6%)0.526463 (34.1%)532 (39.1%)0.439 Negative219 (15.9%)152 (11.0%)178 (13.1%)186 (13.7%)PR status Positive467 (35.1%)293 (22.0%)0.35349 (26.4%)400 (30.3%)0.469 Negative337 (25.3%)235 (17.6%)278 (21.0%)294 (22.3%)HER2 status Positive100 (7.2%)94 (6.8%)**0.01**84 (6.2%)110 (8.1%)0.201 Negative729 (52.7%)460 (33.3%)565 (41.4%)606 (44.4%)Basal status Positive164 (12.4%)110 (8.3%)0.938140 (10.7%)128 (9.8%)0.098 Negative630 (47.7%)418 (31.6%)482 (37.0%)553 (42.4%)Triple-negative status Positive154 (11.2%)96 (7.0%)0.604124 (9.2%)122 (9.0%)0.27 Negative673 (48.9%)452 (32.9%)516 (38.1%)593 (43.8%)Breast cancer-specific survival Alive577 (41.7%)342 (24.7%)**0.01**444 (32.6%)464 (34.0%)0.157 Dead259 (18.7%)207 (14.9%)204 (15.0%)251 (18.4%)Recurrence Present318 (23.0%)255 (18.5%)**0.004**263 (19.3%)305 (22.4%)0.496 Not present510 (36.9%)298 (21.6%)382 (28.1%)411 (30.2%)Distant metastasis Present250 (17.7%)201 (14.2%)**0.017**204 (14.7%)240 (17.2%)0.431 Not present597 (42.3%)364 (25.8%)457 (32.8%)491 (35.3%)*NPI* Nottingham Prognostic Index, *LVI* lymphovascular invasion (determined using IHC), *WLE* wide local excision, *ER* oestrogen receptor, *PR* progesterone receptor, *HER2* human epidermal growth factor receptor 2. Correlations between caspase-3/-8 protein expression and clinicopathologic variables was assessed using Pearson's Chi square test of association (χ²) or Fisher's exact test if in a 2 × 2 tables and cell count was \<5. Significant *P*-values are indicated by bold font

Relationship with clinical outcome {#Sec9}
----------------------------------

High caspase-3, but not caspase-8, expression was significantly associated with adverse disease-specific survival (*P* = 0.008 and 0.056 respectively) (Fig. [3](#Fig3){ref-type="fig"}a, b). In multivariate analysis, including potentially confounding factors of age, tumour size, stage, grade, NPI, lymphovascular invasion, ER, PR and HER2 status (with individual Kaplan--Meier statistics of *P* \< 0.05 for all variables), caspase-3 expression remained significant for breast cancer-specific survival (hazard ratio (HR) 1.347, 95% confidence interval (CI) 1.086--1.670; *P* = 0.007) (Table [4](#Tab4){ref-type="table"}). The caspase-3 and -8 expression was combined to assess their relationship with survival. The combination of high caspase-3 and -8 expression was significantly associated with adverse breast cancer-specific survival in the total patient cohort (*P* = 0.021) (Fig. [3](#Fig3){ref-type="fig"}c); significance was not, however, retained in multivariate analysis using the previous confounding variables (HR 1.069, 95% CI 0.967--1.182; *P* = 0.194).

Fig. 3Kaplan--Meier survival curve analysis showing caspase-3 (*panel A*), caspase-8 (*panel B*) and combinatorial caspase-3 and -8 expression (*panel C*), related breast cancer-specific survival; significance was determined using the log rank test. Numbers below the graph show patients at risk at the specified months. *Panel A* low caspase-3 (**a**) and high caspase-3 (**b**) expression. *Panel B* low caspase-8 (**a**) and high caspase-8 (**b**) expression. *Panel C* low caspase-3/-8 (**a**), high caspase-3/low caspase-8 (**b**), low caspase-3/high caspase-8 (**c**), high caspase-3/high caspase-8 (**d**)

Table 4Cox proportional hazards analysis for breast cancer-specific survivalSig.Exp(B)95% CI for Exp(B)LowerUpperAge0.9391.0130.7241.418Tumour size**0.003**1.5391.1632.037Tumour stage\<**0.001**1.7791.3752.302Tumour grade**0.001**1.5951.1972.125Nottingham prognosis index0.7820.9440.6291.418Lymphovascular invasion\<**0.001**1.5951.2761.993ER status**0.009**1.5281.1092.104PR status**0.001**0.6240.4690.831HER2 status**0.035**1.3621.0221.816Caspase-3**0.007**1.3471.0861.670*Exp (B)* hazard ratio, *95% CI* 95% confidence interval, *ER* oestrogen receptor, *PR* progesterone receptor, *HER2* human epidermal growth factor receptor 2. Significant *P*-values are indicated by bold font

Caspase-3 and -8 expressions were examined for associations with breast cancer-specific survival in different breast cancer subgroups. When analysed in the total patient cohort, caspase-3 expression showed interest in HER2 positive, triple-negative and basal-like diseases (*P* \< 0.001, *P* = 0.004 or *P* = 0.009, respectively, Fig. [4](#Fig4){ref-type="fig"}a--c); whilst caspase-8 expression showed interest in HER2+ and basal-like disease (*P* \< 0.001 or *P* = 0.039, respectively, Fig. [4](#Fig4){ref-type="fig"}d, f). This was further investigated in the individual subgroups (HER2 positive, triple-negative and basal-like). Neither caspase-3 nor caspase-8 protein expression was significantly associated with breast cancer-specific survival in any of the groups (data not shown). In comparison, caspase-3 expression was associated with survival in receptor positive (ER, PR or HER2) and non-basal like subgroups (*P* = 0.001 and 0.029, Fig. [5](#Fig5){ref-type="fig"}a, b). In the receptor positive subgroup, significance was retained in multivariate analysis (HR 1.465, 95% CI 1.150--1.867; *P* = 0.002), including confounding factors of age, tumour size, stage, grade, NPI, lymphovascular invasion, ER, PR and HER2 status (with individual Kaplan--Meier statistics of *P* \< 0.05 for all variables). The significance was also retained in non-basal like patients for multivariate analysis (HR 1.385, 95% CI 1.079--1.777; *P* = 0.01), including the same confounding factors as in receptor positive subgroup (with individual Kaplan--Meier statistics of *P* \< 0.05 for all variables).

Fig. 4Kaplan--Meier survival curves for breast cancer specific-survival based upon caspase-3/caspase-8 expression, showing as different subgroups. *Panel A* caspase-3 expression with HER2 negative and HER2 positive diseases. *Panel B* caspase-3 expression with non-triple negative and triple-negative diseases. *Panel C* caspase-3 expression with non-basal like diseases and basal-like diseases. *Panel D* caspase-8 expression with HER2 negative and HER2 positive diseases. *Panel E* caspase-8 expression with non-triple negative and triple-negative diseases. *Panel F* caspase-8 expression with non-basal like diseases and basal-like diseases

Fig. 5Kaplan--Meier survival curves for breast cancer-specific survival based upon caspase-3 expression in receptor positive subgroup (*panel A*) and non-basal like subgroup (*panel B*). Significance was determined using the log rank test. Numbers below the graph show patients at risk at the specified months. *Panel A, B* high caspase-3 expression (**a**) and low caspase-3 expression (**b**)

Combinational biomarker analysis {#Sec10}
--------------------------------

The relationship between caspase and calpain expression with breast cancer-specific survival was explored. The expression of proteins was grouped (e.g. high caspase/high calpain, low caspase/low calpain, high caspase/low calpain, and low caspase/high calpain). Patients with high caspase-3/high calpain-1 expression, high caspase-3/high calpain-2 expression, high caspase-3/low calpastatin expression, or high caspase-8/low calpain-1 expression had significantly worse breast cancer-specific survival (*P* = 0.005, 0.049, 0.02, and 0.02 respectively) (Table [5](#Tab5){ref-type="table"}). The significance of caspase-3/calpastatin for breast cancer-specific survival was retained in multivariate analysis (HR 1.241, 95% CI 1.053--1.462; *P* = 0.01), when considering previous confounding factors. No other significant association was found between any combinational protein expressions and breast cancer-specific survival in the total patient cohort (data not shown). In subgroup analyses, a significant association was found between caspase-3/calpain-1 and breast cancer-specific survival in the basal-like subgroup (*P* = 0.034), the same pattern shown in the total group (high caspase-3/high calpain-1) that was associated with poor prognosis. However, significance was not retained from multivariate analysis, using previous confounding factors.

Table 5Kaplan Meier survival analyses for breast cancer-specific survival based upon combinatorial protein expressionCalpain-1Calpain-2Calpain-9Calpastatin*P*-valuePatients (N)*P*-valuePatients (N)*P*-valuePatients (N)*P*-valuePatients (N)Total Caspase-3**0.005**994**0.049**9980.139589**0.02**951 Caspase-8**0.02**9710.0569430.0725700.085930HER2+ Caspase-30.5751450.8551410.248890.244135 Caspase-80.3821420.7061380.779860.49133Basal-like Caspase-3**0.034**1970.0591930.2531180.228194 Caspase-80.251900.0541850.3081140.322187TNeg Caspase-30.1091750.2921720.2051080.654175 Caspase-80.5791660.2351630.0711030.291166Kaplan--Meier survival analyses for breast cancer-specific survival based upon combined protein expression in the total patient cohort and different breast tumour phenotypes. Significance was determined using the log-rank test. Significant *P* values are indicated by bold font. *HER2* human epidermal growth factor receptor 2, *TNeg* triple-negative

Discussion {#Sec11}
==========

High caspase-3 expression is significantly associated with adverse disease-specific survival (*P* = 0.008); and remains significant in multivariate analysis when considering potential confounding factors (*P* = 0.007). Caspase-8 was not associated with breast cancer-specific survival. Several studies have suggested that caspase-3 overexpression and enhanced apoptotic activity, is observed in breast carcinomas compared with controls; however, none have shown significant associations between protein expression and patient prognosis \[[@CR21], [@CR35]\]. One study demonstrated that 75% (35 out of 46) of breast tumours lacked caspase-3 transcript and protein expression, and the remaining samples had substantially decreased expression \[[@CR11]\]. This finding was in contrast with previous reports by Nakopoulou et al., in which high caspase-3 protein expression was present in 75.2% (103 out of 137) of invasive breast tumour samples, in comparison with non-neoplastic breast tissues \[[@CR36]\]. Results from the current study suggest that high caspase-3 expression is associated with adverse breast cancer-specific survival in breast cancer patients.

No associations were observed between caspase-8 and clinicopathological criteria. High caspase-3 expression was significantly associated with HER2 positive tumours (*P* = 0.01). Associations between HER2 positive tumours and caspase-3 expression have not been reported previously; however, activation of HER2 can trigger downstream signalling via the phosphatidylinositol kinase 3 (PI3K/AKT) pathways, and AKT signalling has been shown to reduce the activity of caspase-9, the downstream effector of caspase-3 \[[@CR37], [@CR38]\]. Expression of phosphorylated AKT and phosphorylated caspase-9 are significantly correlated in gastric and colorectal cancer \[[@CR39]\]. As discussed before, caspase-3 is the downstream effector of caspase-9; it may be possible that caspase-3 interacts with other substrates and potentially regulates apoptosis through the HER2 signalling pathway.

The prognostic significance of caspase-3 expression in different breast cancer phenotypes was also examined. The Kaplan--Meier subgroup analyses demonstrated a significant association in receptor positive (ER, PR or HER2) and non-basal like subgroups, and remained significant in multivariate analysis. In the case of caspase-8, no significant association was observed in any individual subgroup. The results further emphasised the prognostic importance of caspase-3 in receptor positive and non-basal like patients.

Calpain plays an important role in tumorigenesis, and there is a close link between calpain and caspase protein families. We have previously shown that high calpain-2 expression is associated with worse prognosis in patients with basal-like or triple-negative diseases \[[@CR23]\] and that calpain-1 expression is associated with trastuzumab response in HER2+ breast cancer patients \[[@CR27], [@CR33]\]. Calpain and caspase protein expression was combined to assess associations with breast cancer-specific survival. High caspase-3/high calpain-1, high caspase-3/high calpain-2 and high caspase-3/low calpastatin expression significantly associated with adverse breast cancer-specific survival in the total patient cohort; and combinational caspase-3/calpain-1 has important prognostic value in basal-like patients. Only caspase-3/calpastatin expression was identified as an independent factor for breast cancer-specific survival from multivariate analysis. It is important to note that this study focuses on the expression levels of functionally significant proteases, without assessing their activity. It would be interesting to investigate the relationship between patient prognosis and active caspases and calpains as part of any future work. Antibodies are available for caspase-3 and -8 and different methodologies are used to detect their activities; however no published studies have investigated their expression in breast cancer \[[@CR40], [@CR41]\]. Antibodies have been described that are able to determine calpain activity through the detection of specific calpain-cleaved products; however these antibodies have not been optimised for use in human tumour tissue \[[@CR42], [@CR43]\].

The current study demonstrates that high caspase-3 expression is significantly associated with adverse breast cancer-specific survival, and remains so in multivariate analysis including potential confounding factors. Caspase-8 expression is not associated with breast cancer-specific survival. Further subgroup analyses demonstrate that caspase-3 and -8 expression are important in distinct breast cancer phenotypes. Caspase-3 and -8 expression was combined with calpain expression to provide important information on evaluating patient outcome in basal-like phenotype disease. Further validation is warranted to confirm if determining caspase-3 with/without calpain expression would be of clinical benefit.
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